Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting
April 22, 2015 at 07:32 AM EDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today presented data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being ...